ASHP shall hold a Second Residency Match from March 2016.

The old ‘scramble’ solution to fill open positions is no longer the best option due to the rapid upsurge in the number of positions and also the amount of unmatched candidates recently, stated Janet Silvester, Pharm.D., M.B.A., FASHP, vice president, ASHP Accreditation Services Office. This fresh second Match shall ensure that a predictable, fair process is designed for both learning college students and residency programs. Silvester added that a Post-Match Scramble will become held after the Phase II Match still, but that ASHP predicts it’ll include far fewer applications and applicants than in the past. The new Stage II Match procedure requires that all pharmacy residency applications in the accreditation process participate in PhORCAS this fall.The principal endpoint for this study was SVR 24 weeks after last treatment. The scholarly research was conducted on 1088 treatment-naive HCV patients, all of whom acquired genotype 1. For the three arms of the trial, one band of patients was treated with 750 mg of telaprevir every eight hours in conjunction with peginterferon alfa-2a 180 ug/week and ribavirin 1000-1200 mg/time for 12 weeks, while the second group was given the same treatment but for only 8 weeks. SVR was 75 % for all those receiving telaprevir combination treatment for 12 weeks, 69 % for all those receiving telaprevir mixture treatment for eight weeks, and 44 % for those receiving standard of care.

Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric stable tumors at ASCO Perifosine proven tolerable and safe, with early signals of clinical benefit in advanced refractory pediatric neuroblastoma patients Aeterna Zentaris Inc.